Practical Questions about Clinical Trials with T Cell Engagers скачать в хорошем качестве

Practical Questions about Clinical Trials with T Cell Engagers

What does it really look like to take part in a clinical trial for a T cell engager therapy? In this Q&A video, Dr. Ricardo Grieshaber-Bouyer answers practical, real-world questions about clinical trials using T cell engagers, including CLN-978, an investigational therapy being studied for autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren’s disease. Dr. Grieshaber-Bouyer is joined by a prospective clinical trial participant and three patients living with lupus, rheumatoid arthritis, and Sjögren’s disease, who ask honest questions about safety, eligibility, side effects, treatment logistics, and what participation in an early-phase clinical trial actually involves. Topics covered include: What happens on a treatment day in a Phase 1 clinical trial Potential side effects and safety monitoring Who early-stage trials are designed for What “treatment-free remission” could mean How patients may access investigational therapies Participation in a clinical trial is voluntary, and eligibility is determined by a study physician. To learn more about CLN-978, visit: https://linktr.ee/cln978 This video was developed with support from Cullinan Therapeutics.